• September - i3 Pharmaceuticals was formed with strong capital backing from private investors. 
  • October – Leased laboratory space in Plymouth Meeting, PA.


  • January - Acquired a 150,000 square feet building in Warminster, PA.
  • December - Moved into the newly constructed facility with state of the art research and analytical laboratories, pilot & commercial manufacturing plants and warehouse.


  • June – Filed first ANDA with the US FDA for a product for which there was formerly no generic alternative available.
  • December - Successful FDA Prior Approval and GMP inspection.


  • April - Gained FDA ANDA approval for Ramelteon 8mg tablets.
  • September - Gained FDA ANDA approval for Chlorzoxazone 375 and 750mg tablets.


  • June - Successful FDA full, virtual GMP inspection.
  • September - Gained FDA ANDA approval for Selegiline HCl 5mg tablets.


  • February - Launched Selegiline HCl 5mg tablets into US Market. First product commercialized in the i3 label.
  • October - Launched Ranolazine 500mg and 1000mg extended-release tablets into US Market.


  • March - Successful FDA cGMP Inspection and five-product Prior Approval Inspection.
  • October - Launched Posaconazole DR 100mg tablets into US Market.
  • November - Launched Maraviroc 150mg and 300mg tablets into US Market.
  • December - Launched Guanfacine 1mg and 2mg tablets into US Market.